NASDAQ NMS - GLOBAL MARKET · GYRE
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Gyre Therapeutics Inc

Gyre Therapeutics Inc

Biotechnology
$6.91
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Analyst data unavailable at compute time · Sentiment absence reason unknown
GYRE
Gyre Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

50/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GYRE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GYRE catalysts
About Gyre Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
618
Country
US

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.91
Last session
Day high
$6.91
Last session
Day low
$6.91
Last session
Previous close
$6.91
52W high
$8.87
-22.10% from high
52W low
$5.56
41% of range
Market cap
$732.7M
P/E
146.60×
EPS
$-0.1900
Beta
0.93
Shares out
106M
Avg volume
55K
VWAP
$6.91
Last session
Price history computed in-house
1W
+1.47%
1M
+16.33%
3M
+16.33%
1Y
-15.53%
YTD
-2.12%
SMA 50 $6.38 · above
SMA 200 $7.20 · below
52W position 41%

GYRE overview

Veridion Score
50
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GYRE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GYRE Form 4 filings
Public disclosures

Congress activity in GYRE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GYRE in the cached public ledger.

Federal contracts

GYRE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GYRE in this window.
Lobbying spend

GYRE lobbying filings, year to date.

Registered lobbying filings matched to Gyre Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GYRE in this window.
Loading news for GYRE
Analyst ratings
Sovereign unlock shows live analyst consensus for GYRE.
Options
Sovereign unlock shows live options positioning for GYRE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.